Using AMNet to Track Opioid Use Disorder Treatment Outcomes
-
Register
- Non-Member - Free!
- Regular Member - Free!
- Retired - Free!
- Early Career Physician - Free!
- Resident - Free!
- Student - Free!
- Associate - Free!
- ASAM Staff - Free!
- International Member - Free!
- Emeritus Member - Free!
- Provisional Member - Free!
- Fellow Member - Free!
- Honorary Member - Free!
- CRT Member - Free!
Using AMNet to Track Opioid Use Disorder Treatment Outcomes
Opioid use disorder is a chronic, relapsing disease, which has significant economic, personal, and public health consequences. The ASAM National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use was developed to assist in the evaluation and treatment of opioid use disorder. Topics covered included: opioid withdrawal management, psychosocial treatment, special populations, and opioid overdose.
This webinar outlines the highlights of the 2020 Focused Update of the National Practice Guideline for the Treatment of Opioid Use Disorder, focusing on the several new buprenorphine formulations recently approved by the FDA. The webinar also outlines AMNet measures that can be used to track implementation of the guidelines and treatment outcomes.
AMNET is an Addiction Medicine practice-based research network. Learn more and join the network here.
Session Information
Date: This webinar was live on Wednesday, January 27, 2021, this session is now available on-demand as a recorded webinar.
Speaker(s):
- Kyle Kampman, MD, FASAM
- Brian Hurley, MD, MBA, DFASAM
Learning Objectives
By completing this session, you will be able to:
- Summarize the guideline’s new and updated treatment recommendations and discuss how they should be used in practice.
- Address the changing epidemiology of opioid use disorder and the remaining gaps in the treatment of OUD.
- Apply AMNet measures to track implementation of the guideline and provide measurement-based care.
Kyle M. Kampman
MD, FASAM
Kyle Kampman, MD, FASAM graduated from Northwestern University in 1981 and Tulane University School of Medicine in 1985. He interned at the National Naval Medical Center at Bethesda, Maryland, and served as a medical officer in the United States Navy from 1985 until 1990. He came to the University of Pennsylvania and served as a resident in Psychiatry from 1990 until 1993. He then completed a fellowship in Addiction Psychiatry. In 1994 he joined the faculty in the Department of Psychiatry as an assistant professor. He was promoted to associate professor in 2003 and to professor in 2012. Dr. Kampman has had extensive experience in the treatment of alcohol, cocaine, and opioid dependence. He chaired the committee that wrote the ASAM National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. He has conducted a number of trials testing medications for the treatment of cocaine, alcohol, and opioid dependence and is a recognized authority on the cocaine withdrawal syndrome. In addition to research, he works at the Addiction Recovery Unit of the Philadelphia VA Medical Center, where he continues to treat cocaine, alcohol, and opioid-dependent patients with both medications and psychotherapy.
No relevant financial relationships
Brian Hurley
MD, MBA, DFASAM
Los Angeles Country Department of Health Services
Brian Hurley, MD, MBA, DFASAM is an addiction physician and the Director of Addiction Medicine for the Los Angeles County Department of Health Services. As Director-at-Large, Brian currently serves as a board member of ASAM and gives presentations around the world regarding addiction medicine. He co-chairs the Los Angeles County Department of Health Services’ Substance Use Disorders Workgroup and the SafeMedLA Medications for Addiction Treatment Action Team, and is the Clinical Director of the Treatment Starts Here program through the Center for Clinical Innovation, focused on increasing the delivery of medications for addiction treatment in California’s community health centers.
He is a senior researcher at the Friends Research Institute and is a primary investigator on a Tobacco Related Disease Prevention Program-funded project integrating smoking cessation services into community mental health centers and patient-centered medical homes and is the grant lead for three Medications for Addiction Treatment Access Points projects funded by the Sierra Health Foundation supporting access to medications for addiction treatment across Los Angeles County.
He is also a co-investigator for several Rand Corporation projects evaluating the integration of substance use disorder treatment within community mental health and Federally Qualified Health Center settings. He also serves on the American Board of Psychiatry and Neurology’s Addiction Psychiatry Examination Writing Committee. Brian completed the Robert Wood Johnson Foundation Clinical Scholars Program at the University of California, Los Angeles (UCLA) and is an alumnus of the Massachusetts General Hospital and McLean Hospital Psychiatry Residency Training Program and the New York University Addiction Psychiatry Fellowship. Additionally, he has served in various roles for the Massachusetts Society of Addiction Medicine, New York Society of Addiction Medicine, and California Society of Addiction Medicine.
No Relevant Financial Disclosures
Credits and Disclosures
ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
National Board for Certified Counselors ACEP
The American Society of Addiction Medicine has been approved by NBCC as an Approved Continuing Education Provider, ACEP No. 7062. Programs that do not qualify for NBCC credit are clearly identified. The American Society of Addiction Medicine is solely responsible for all aspects of the programs.
NAADAC, the Association for Addiction Professionals
This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.
California Association for Drug/Alcohol Educators (CAADE)
This educational program is approved by CAADE: #CP40 999 1222
California Association of DUI Treatment Centers (CADTP)
This educational program is approved by CADTP: #205
California Consortium of Addiction Programs and Professionals (CCAPP)
This educational program is approved by CCAPP: #OS-20-330-1222
Continuing Education Credits (CEUs)
Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.
Maintenance of Certification
American Board of Preventive Medicine (ABPM)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 8 LLSA credits towards ABPM MOC Part II requirements.
American Board of Anesthesiology (ABA)
This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.
American Board of Pediatrics (ABP)
Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 8 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.
American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credits.
American Board of Surgery (ABS)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and/or Self-Assessment requirements of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit
American Board of Psychiatry and Neurology (ABPN)
Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.
American Board of Addiction Medicine (ABAM)
Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.
CME Reviewer and Disclosure Information
ASAM CME Committee Reviewer
Edwin A. Salsitz, MD, DFASAM – No Relevant Financial Disclosures
Program Planning Committee, CME Committee, Medical Education Council (MEC), and Faculty Disclosure Information
In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
Faculty and Planning Committee
Faculty Disclosure Information
Kyle M. Kampman, MD, FASAM – Does Disclose
- Alkermes, Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support), Clinical Condition: Opiate Use Disorder
- World meds, Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support), Clinical Condition: Opiate Use Disorder
Brian Hurley, MD, MBA, DFASAM - No Relevant Financial Disclosures
Planning Committee Disclosure Information
Frank Vocci, PhD – Does Disclose
- Cardiol Therapeutics, Clinical Condition: OUD, Consultant/Advisory Board, Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support), Cardiol would supply CBD for a clinical trial funded by NIDA
- Braeburn Pharma, Clinical Condition OUD, Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support), If other, please describe: receipt of drug for a clinical trial
- Lyndra Pharma, Clinical Condition, OUD, Consultant/Advisory Board
Anna Pagano, PhD – No Relevant Financial Disclosures
Key:
Complete
Next
Failed
Available
Locked